Key facts
- It has raised $7.0M; the latest was Early Stage VC ($7.0M) in Jul 2025.
- Notable investors include Center for Creative Economy and Innovation, FuturePlay, IBK Venture Investment, Stic Alternative, AJU IB Investment — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Neumous
- ·The full record, as it builds
Funding rounds
No funding rounds for Neumous are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neumous
Developer of therapeutic ultrasound medical devices intended to open the blood-brain barrier. The company's technology uses a non-invasive approach and sonicate ultrasound to a specific brain region to effectively deliver therapeutic agents or drugs into the brain, enabling the healthcare sector to treat various brain diseases such as brain tumors and Alzheimer's.
- Sector
- Healthcare
- HQ
- Cheongju, South Korea
- Founded
- 2022
- Website
- neumous.com/
- Ownership
- Privately Held (backing)
Neumous doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neumous shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neumous in its N-PORT filings yet. We sweep new filings monthly.